Multiple myeloma learning Center
This Learning Center is a freely accessible educational platform for healthcare providers who may be involved in the identification and management of patients with multiple myeloma. Our goal is to ensure that you—the practicing clinician—have access to the most accurate, up-to-date information for the treatment of patients with this challenging clinical scenario.
We encourage you to share this educational resource with your colleagues and your healthcare team.
Activities
Navigating the Bridge to CAR-T: Conversations and Cases on Individualized Bridging Strategies
Physician Credit Available: 1.0 AMA PRA Category 1 Credit(s)™
Nurse Credit Available: 1.0 ANCC contact hours
Pharmacist Credit Available: 1.0 ACPE contact hours
Explore the critical role of bridging therapy for patients with relapsed/refractory multiple myeloma preparing for CAR-T cell therapy. This program highlights key trial insights, current evidence, and practical strategies to individualize BT, control disease, manage toxicity, and potentially improve post-CAR-T outcomes—equipping clinicians with the knowledge to optimize care in this rapidly evolving field.
Course Director: Saad Z. Usmani, MD, MBA, FACP, FASCO
Course Faculty: Rahul Banerjee, MD, FACP and Doris K. Hansen, MD
Charting the Course to Improved Outcomes in Multiple Myeloma: Refining First-line Treatment Strategies With Anti-CD38–Based Quadruplet Regimens
Physician Credit Available: 0.75 AMA PRA Category 1 Credit(s)™
Nurse Credit Available: 0.75 ANCC contact hours
Pharmacist Credit Available: 0.75 ACPE contact hours
Despite increasing evidence supporting anti-CD38–based quadruplet regimens in newly diagnosed multiple myeloma (NDMM), their integration into routine clinical practice remains suboptimal. Many clinicians are uncertain about optimal patient selection, regimen choice, and supportive care strategies, particularly given the nuanced efficacy and safety profiles of available agents and evolving administration options. In this program, expert faculty will review the latest data on daratumumab- and isatuximab-based quadruplets in transplant-eligible and -ineligible patients, including mechanisms of action, trial results, and guideline recommendations. Learners will gain practical insights into applying risk-adapted treatment selection, managing toxicities, and incorporating novel delivery methods. Interactive case discussions will highlight how to navigate real-world barriers and personalize care based on comorbidities, performance status, and treatment goals. This education is designed to close critical gaps in knowledge and confidence, empowering clinicians to optimize outcomes across the NDMM spectrum.
Course Director: Saad Z. Usmani, MD, MBA, FACP, FASCO
Course Faculty: Nisha S. Joseph, MD; Carlyn Tan, MD
Charting the Course to Improved Outcomes in Multiple Myeloma: Maximizing the Impact of T-cell–Engaging Therapies in Relapsed/Refractory Patients
Physician Credit Available: 1.0 AMA PRA Category 1 Credit(s)™
Nurse Credit Available: 1.0 ANCC contact hours
Pharmacist Credit Available: 1.0 ACPE contact hours
Despite recent advances, the management of relapsed/refractory multiple myeloma (RRMM) remains challenging, particularly in heavily pretreated patients with limited therapeutic options. T-cell–engaging therapies, including chimeric antigen receptor (CAR)-T cell therapies and bispecific antibodies (BsAbs), have emerged as transformative modalities with distinct mechanisms of action, safety profiles, and logistical considerations. In this program, expert faculty will review key clinical trial data supporting the use of FDA-approved BsAbs and anti-BCMA CAR-T cell therapies, focusing on patient selection, adverse event mitigation, and practical integration into clinical workflows. Learners will gain critical insights into managing unique toxicities such as CRS and neurotoxicity, coordinating care with specialized centers, and addressing complexities of outpatient and inpatient administration. Through interactive cases and real-world strategies, this activity will close educational gaps in the use of novel immunotherapies for RRMM to help participants apply these cutting-edge treatments safely and effectively across diverse clinical settings.
Course Director: Saad Z. Usmani, MD, MBA, FACP, FASCO
Course Faculty: Rahul Banerjee, MD, FACP; Nisha S. Joseph, MD; Carlyn Tan, MD
Bringing Advances in Myeloma Care to the Community: Navigating Real-world Challenges and Practical Solutions to Optimize Outcomes With Bispecific Antibody Therapy
Physician Credit Available: 0.75 AMA PRA Category 1 Credit(s)™
Nurse Credit Available: 0.75 ANCC contact hours
Pharmacist Credit Available: 0.75 ACPE contact hours
Despite recent approvals and promising clinical efficacy of bispecific antibody (BsAb) therapies for relapsed/refractory multiple myeloma (RRMM), significant educational gaps remain—particularly in community settings—regarding optimal patient selection, treatment initiation, and management of associated toxicities. This gap contributes to suboptimal adoption and use of BsAb therapies, impacting patient outcomes. In this program, learners will explore the current challenges of integrating BsAbs into RRMM treatment paradigms, including the lack of clear guidelines for individualized therapy selection and sequencing. Participants will gain practical insights into BsAb administration, including dosing, monitoring, and management of unique adverse events. The activity will address real-world barriers for community oncology providers, including logistical challenges of transitioning BsAb therapies to outpatient settings and overcoming disparities in care delivery. By closing these gaps, clinicians will be equipped with the knowledge and tools necessary to safely and effectively incorporate BsAb therapies into routine clinical practice for patients with RRMM.
Course Director: Saad Z. Usmani, MD, MBA, FACP, FASCO
Course Faculty: Rahul Banerjee, MD, FACP; Nisha S. Joseph, MD; Carlyn Tan, MD